読み込み中
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
前日終値
$17.85
−$0.36 · -1.98%
時間外
$17.95
+$0.10 · +0.56%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $17.85
52週レンジ
現在 $17.85
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
80
割安
センチメント
71
強気
リスク
45
やや高いリスク
モメンタム
45
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $17.85
52週レンジ
現在 $17.85
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 21.98億 USD | 19.02億 USD | 12.43億 USD | 9.33億 USD | 7.02億 USD |
| 売上原価 | 8.82億 USD | 3.19億 USD | 1.5億 USD | 1.4億 USD | 9704.9万 USD |
| 粗利益 | 13.17億 USD | 15.83億 USD | 10.93億 USD | 7.93億 USD | 6.05億 USD |
| 研究開発 | 15.22億 USD | 8.05億 USD | 8.77億 USD | 8.77億 USD | 7.71億 USD |
| 販売・一般管理 | 4.79億 USD | 5.58億 USD | 4.82億 USD | 4.51億 USD | 2.83億 USD |
| 営業費用 | 19.75億 USD | 13.65億 USD | 13.61億 USD | 13.29億 USD | 10.65億 USD |
| 受取利息 | 1956.9万 USD | 7176.7万 USD | 8596.9万 USD | 2772.3万 USD | 51.1万 USD |
| 支払利息 | 973.1万 USD | 1839.1万 USD | 2201万 USD | 5324.8万 USD | 6352.5万 USD |
| 減価償却費と償却費 | 4452.1万 USD | 3772.4万 USD | 4439.7万 USD | 4186.4万 USD | 3801.7万 USD |
| 営業利益 | −6.58億 USD | 2.18億 USD | −2.68億 USD | −5.36億 USD | −4.6億 USD |
| 純利益 | −7.13億 USD | 2.35億 USD | −5.36億 USD | −7.03億 USD | −4.19億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2012年7月12日 | 1:6 | — | — |
発効済み 2012年7月12日
1:6
この株式へのエクスポージャーを報告している上場投資信託です。
First Trust NYSE Arca Biotechnology Index FundFBT8700.09万3.07%28.37億 USD0.55%$265.4+2.00%
Vanguard Morningstar Total Stock Market ETFVTI6718.61万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI5591.87万0.55%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM4983.51万0.06%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB4849.45万0.03%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2778.35万0.06%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF2584.23万0.03%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1769.24万0.11%158.4億 USD0.03%$53.45+0.17%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
